Oxycodone HydrochlorideEndone
Not recommended mixed outcome Pain 💬 consumer voice
Modified release oxycodone 5 mg strength for pain management in patients unresponsive to non-opioid analgesics.
1
Submissions
2015–15
On the record
—
ICER range
Not modelled
Cost basis
Decisions on record
The committee reached more than one outcome for this medicine at its most recent sitting — different indications were decided differently. The header reflects the least favourable of them; all are listed below.
- Meeting Mar 2015 Not recommended Pain
- Meeting Mar 2015 Deferred Chronic pain
- Meeting Nov 2008 Recommended Narcotic analgesic no PSD
Access path
- TGA registered · Endone
- Mar 2015Not recommended
no pressing clinical need established for the strength; previous strength was de-listed after sponsor established no…
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
7.1 The PBAC rejected the proposed General schedule listing of the oxycodone 5 mg strength.PSD · Mar 2015
7.2 The PBAC noted that another sponsor’s 5mg presentation of oxycodone had been removed from the PBS at the request of that sponsor. The PBAC recalled that as a standard part of a request to delist a product from the PBS, it must be established that there is no pressing clinical need for the product in question.PSD · Mar 2015
Economic analysis
6.3 The submission proposed that the 5 mg strength be priced approximately ''''''% less than the current AEMP for Targin (oxycodone + naloxone) 5mg/2.5mg.PSD · Mar 2015
Cost-effectiveness
No economic analysis performed; this was a minor submission for a strength variation of an existing product.
The PBAC noted that the submission did not provide financial estimates. PBAC · 2015
Decision context
PopulationPatients requiring modified release oxycodone 5 mg for pain management.
Why it was knocked back
- no pressing clinical need established for the strength; previous strength was de-listed after sponsor established no clinical need; submission did not provide financial estimates; did not establish convincing argument that clinical need now existed
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2015 | Not recommended | — | — | Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Oxycodone76%Oxycodone With Naloxone71%Oxycodone Hydrochloride + Naloxone Hydrochloride71%Buprenorphine; Oxycodone + Naloxone68%Oxycodone Hydrochloride With Naloxone Hydrochloride Dihydrate66%Oxycodone Hydrochloride And Naloxone Hydrochloride Dihydrate66%Oxycodone, Tramadol, Codeine, Hydromorphone, Morphine, Tapentadol, Buprenorphine, Fentanyl66%Morphine Hydrochloride65%